Biogen Inc. ((BIIB)), Biogen ((CC:HTER)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Biogen Inc. is currently conducting a Phase 3 clinical study titled ‘A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Felzartamab in Adults With IgA Nephropathy (PREVAIL).’ The study aims to assess the effects of felzartamab on proteinuria and kidney function in adults with Immunoglobulin A Nephropathy (IgAN), a condition characterized by protein in the urine due to kidney damage.
The intervention being tested is felzartamab, administered intravenously, designed to reduce proteinuria and improve kidney filtration. Participants are randomly assigned to receive either felzartamab or a placebo, with neither the participants nor the researchers aware of the group assignments, ensuring unbiased results.
This interventional study employs a randomized, parallel assignment model with quadruple masking (participant, care provider, investigator, outcomes assessor) to maintain objectivity. The primary purpose is to evaluate the treatment’s efficacy.
The study began on May 8, 2025, with a primary completion date expected in 2027. The most recent update was submitted on August 19, 2025. These dates are crucial for tracking progress and anticipating results.
Biogen’s study could significantly impact its stock performance and investor sentiment, especially if felzartamab proves effective. Success in this study could position Biogen favorably against competitors in the nephrology market, potentially leading to increased market share.
The study is ongoing, with further details available on the ClinicalTrials portal.